Keping Chen

Dr. Keping Chen


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Heart Rhythm
Verified
Journal Article
Closed access
YLYuqiu Li
Yuqiu Li
KCKeping Chen
Keping Chen
YDYan Dai
Yan Dai
CLChao Li
Chao Li
QSQi Sun
Qi Sun
SZShu Zhang
Shu Zhang

19 September 2019 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
KCKeping Chen
Keping Chen
YLYuqiu Li
Yuqiu Li

5 November 2022 in Heart Rhythm
Verified
Journal Article
Closed access
QHQingyun Hu
Qingyun Hu
HYHongzhao You
Hongzhao You
KCKeping Chen
Keping Chen
YDYan Dai
Yan Dai
WLWenzhao Lu
Wenzhao Lu
SZShu Zhang
Shu Zhang

26 December 2022 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
SWSijin Wu
Sijin Wu
WLWenzhao Lu
Wenzhao Lu
CZChen Zhongli
Chen Zhongli
YDYan Dai
Yan Dai
KCKeping Chen
Keping Chen
SZShu Zhang
Shu Zhang
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been highly recommended for glycemic control and weight reduction. However, evidence has accumulated that GLP-1 RAs treatment is related to an increase in heart rate, which could potentially induce cardiac arrhythmias. This study aims to investigate the association of GLP-1 RAs therapy with incident arrhythmias in diabetic and obese patients. Methods: MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were systematically searched from inception up to May 25, 2022. Randomized controlled trials (RCTs) comparing GLP-1 RAs with placebo or active control for adults with type 2 diabetes or obesity were included. The outcomes of interest were prespecified as incident atrial fibrillation (AF), atrial flutter (AFL), ventricular arrhythmias (VAs), and sudden cardiac death (SCD). Mantel-Haenszel relative risk (MH-RR) with a corresponding 95% confidence interval (95% CI) was estimated using a fixed-effects model. Results: A total of 56 RCTs involving 79,720 participants (44,028 GLP-1 RAs vs 35,692 control: mean age 57.3 years) were included from 7692 citations. GLP-1 RAs use overall did not significantly increase the risk of AF (RR 0.97, 95% CI 0.83–1.12), AFL (RR 0.83, 95% CI 0.59–1.17), VAs (RR 1.24, 95% CI 0.92–1.67), and SCD (RR 0.89, 95% CI 0.67–1.19), compared with controls. In further subgroup analyses, we observed an increasing trend toward incident AF with dulaglutide (RR 1.40, 95% CI 1.03–1.90) while an inverse trend with oral semaglutide (RR 0.43, 95% CI 0.21–0.87). Additionally, higher doses of GLP-1 RAs (RR 1.63, 95% CI 1.11–2.40) and higher baseline BMI (RR 1.60, 95% CI 1.04–2.48) might significantly increase the risk of VAs. No significant differences were identified in other subgroup analyses. Conclusions: GLP-1 RAs therapy was not associated with an overall higher risk of arrhythmias, demonstrating an assuring cardiovascular safety profile. Further studies are required to determine whether the potential antiarrhythmic or arrhythmogenic effect of GLP-1 RAs is drug-specific and varies from doses or baseline BMI. Trial registration: PROSPERO Identifier: CRD42022339389.

1 June 2021 in Heart Rhythm
Verified
Journal Article
Closed access
JLJinxuan Lin
Jinxuan Lin
QHQingyun Hu
Qingyun Hu
KCKeping Chen
Keping Chen
YDYan Dai
Yan Dai
RCRuohan Chen
Ruohan Chen
SZShu Zhang
Shu Zhang

1 August 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
JLJinxuan Lin
Jinxuan Lin
KCKeping Chen
Keping Chen
YDYan Dai
Yan Dai
QSQi Sun
Qi Sun
YLYuqiu Li
Yuqiu Li
SZShu Zhang
Shu Zhang
Background: Left bundle branch pacing (LBBP) is a technique for conduction system pacing, but it often results in right bundle branch block morphology on the ECG. This study was designed to assess simultaneous pacing of the left and right bundle branch areas to achieve more synchronous ventricular activation. Methods: In symptomatic bradycardia patients, the distal electrode of a bipolar pacing lead was placed at the left bundle branch area via a transventricular-septal approach. This was used to pace the left bundle branch area, while the ring electrode was used to pace the right bundle branch area. Bilateral bundle branch area pacing (BBBP) was achieved by stimulating the cathode and anode in various pacing configurations. QRS duration, delayed right ventricular activation time, left ventricular activation time, and interventricular conduction delay were measured. Pacing stability and short-term safety were assessed at 3-month follow-up. Results: BBBP was successfully performed in 22 of 36 patients. Compared with LBBP, BBBP resulted in greater shortening of QRS duration (109.3±7.1 versus 118.4±5.7 ms, P <0.001). LBBP resulted in a paced right bundle branch block configuration, with a delayed right ventricular activation time of 115.0±7.5 ms and interventricular conduction delay of 34.0±8.8 ms. BBBP fully resolved the right bundle branch block morphology in 18 patients. In the remaining 4 patients, BBBP partially corrected the right bundle branch block with delayed right ventricular activation time decreasing from 120.5±4.7 ms during LBBP to 106.1±4.2 ms during BBBP ( P =0.005). Conclusions: LBBP results in a relatively narrow QRS complex but with an interventricular activation delay. BBBP can diminish the delayed right ventricular activation, producing more physiological ventricular activation. Graphic A graphic abstract is available for this article.